Gene Therapy GS010 Is Safe, Well Tolerated by LHON Patients in Phase 1/2 Trial – Mitochondrial Disease News
Mitochondrial Disease News |
Gene Therapy GS010 Is Safe, Well Tolerated by LHON Patients in Phase 1/2 Trial
Mitochondrial Disease News “If these promising results are confirmed in the ongoing Phase 3 studies, GS010 would offer a meaningful and life-changing therapy for those so afflicted and become the standard of care for LHON,” she said. GS010 is a gene therapy designed by GenSight … |
